CJC-1295 + Ipamorelin: What It Is and What It Does

What CJC-1295 + Ipamorelin is

This is a two-in-one research blend: CJC-1295 (a copy of the 'release growth hormone' signal, GHRH) plus Ipamorelin (which pushes the same system from a different angle). It is supplied as an analytical-grade reference material for laboratory research.

Where it comes from

This is not a single discovered molecule but a research pairing of two separately developed compounds. CJC-1295 is a long-acting analog of growth-hormone-releasing hormone (GHRH), created in the early 2000s; ipamorelin is a selective growth-hormone secretagogue first described in 1998. Each was designed to switch on growth-hormone release, but through a different receptor. Combining a GHRH-type peptide with a ghrelin-receptor secretagogue is a long-standing experimental design in endocrinology, because the two signals reinforce one another — so the 'blend' reflects that established two-pathway approach rather than a new discovery.

What it does — in plain terms

The body's growth-hormone system has more than one 'go' button. CJC-1295 presses one of them (the GHRH signal); Ipamorelin presses another (the ghrelin/secretagogue signal). Pairing them is a common research design, because pressing two buttons at once is a cleaner way to study how the system responds. Ipamorelin is also of interest because it's 'selective' — it nudges growth hormone without stirring up other hormones as much.

How it works

The body's growth-hormone system has more than one 'go' button, and this blend presses two of them at once. CJC-1295 acts on the GHRH receptor — the pathway the brain normally uses to request a pulse of growth hormone. Ipamorelin acts on a different receptor, the ghrelin/secretagogue receptor (GHS-R1a), which serves as an amplifier of that same release. (For the primary studies behind each one, open its own post.)

Pairing a GHRH analog with a secretagogue is a classic endocrine experiment because the two pathways are complementary: stimulating them together tends to produce a larger, cleaner pulse of growth hormone than either alone, while still working through the body's own pituitary rather than adding growth hormone from outside. Ipamorelin contributes selectivity — the original research emphasized that it releases growth hormone without meaningfully raising cortisol or prolactin — which is part of why it is a favored partner in these pairings.

It is worth being clear about the evidence: the provided literature centers on ipamorelin and on growth-hormone secretagogues as a class, rather than on this specific two-peptide combination. So the blend is best understood as a way to study the two release pathways side by side, with the strongest primary data sitting in each component's own record.

What the research shows

Most of the published work here is about ipamorelin specifically, or about growth-hormone secretagogues in general — not head-to-head trials of the CJC-1295-plus-ipamorelin combination itself, and much of it is preclinical (animal and cell studies) with a couple of early human pharmacokinetic reports. Read this as background on the two pathways rather than proof of the blend, and see each component's post for its primary studies. With that context, here is what the provided work reports.

• Physiology & Behavior, 2024 — examined whether ipamorelin could counter body-weight decline and appetite loss in an animal model of chemotherapy-associated wasting (cachexia).
• European Journal of Endocrinology, 1998 — characterized ipamorelin as the first selective growth-hormone secretagogue, releasing growth hormone in animal models without meaningfully raising cortisol or prolactin.
• JAAOS Global Research & Reviews, 2026 — reviewed therapeutic peptides in orthopaedics, placing growth-hormone secretagogues such as ipamorelin within the broader landscape of research peptides.
• Growth Hormone & IGF Research, 1999 — found that ipamorelin induced longitudinal bone growth in rats, a downstream marker of growth-hormone activity.
• Pharmaceutical Research, 1999 — modeled the pharmacokinetics of ipamorelin in human volunteers, describing how the peptide is cleared and how growth-hormone release tracks it.
• Xenobiotica, 1998 — evaluated the pharmacokinetics of ipamorelin and related secretagogues, with emphasis on nasal absorption as a delivery route.
• Bioorganic & Medicinal Chemistry Letters, 2001 — reported chemistry work on growth-hormone-secretagogue hybrids built from ipamorelin, exploring how structure shapes activity.
• Translational Andrology and Urology, 2020 — reviewed growth-hormone secretagogues and their studied effects on body composition.
• Histology and Histopathology, 2002 — examined how prolonged administration of ipamorelin affected the pituitary's growth-hormone-producing (somatotroph) cells in young rats, studied in vitro.
• Growth Hormone & IGF Research, 2001 — studied whether ipamorelin could offset steroid-induced bone loss in rats, another readout of growth-hormone and IGF-1 activity.

What CJC-1295 + Ipamorelin is studied for

Two release pathways together. The whole point of the pairing: CJC-1295 drives the GHRH receptor while ipamorelin drives the ghrelin/secretagogue receptor, letting researchers study how the two complementary signals combine to release growth hormone.

Selective secretagogue signaling. Ipamorelin's contribution is selectivity — foundational research described it releasing growth hormone without meaningfully raising cortisol or prolactin, which makes the combined signal cleaner to interpret.

Downstream growth-hormone effects. Component studies in animals tracked classic readouts of growth-hormone activity, such as longitudinal bone growth and steroid-related bone loss, to confirm the axis is being switched on.

Pharmacokinetics of the components. Early human and animal studies mapped how ipamorelin is cleared and absorbed, groundwork for understanding how a secretagogue behaves before it is paired with a GHRH analog.

Storage & handling

As a lyophilized powder, this CJC-1295-plus-ipamorelin blend keeps best cold and dark — refrigerated for the near term, frozen for longer storage. Once reconstituted with bacteriostatic water it should be held at roughly 2–8 °C, protected from light, and shielded from repeated freeze-thaw cycles, which degrade peptides. Because it contains two peptides, handle it gently and use it promptly after reconstitution; see the reconstitution reference below for the concentration math. For laboratory research use only.

Reconstitution reference

Standard laboratory reconstitution volumes for CJC-1295 + Ipamorelin, from the VNG Reconstitution Sheet. See the full reconstitution guide for the method and concentration math.